Cases reported "Carcinoma in Situ"

Filter by keywords:



Filtering documents. Please wait...

1/14. Polyarthritis as a complication of intravesical bacillus Calmette-Guerin immunotherapy for bladder cancer.

    bacillus Calmette-Guerin (BCG) is the most effective agent currently available for the treatment of superficial bladder cancer. However, this form of treatment is associated with some complications, including arthritis. In this report, we present a 69-year-old woman who developed inflammatory polyarthritis following BCG treatment for superficial bladder cancer. The arthritis resolved following treatment with a non-steroidal anti-inflammatory drug and chloroquinine.
- - - - - - - - - -
ranking = 1
keywords = bacillus
(Clic here for more details about this article)

2/14. Complications of intravesical bacillus Calmette-Guerin: a case report.

    bacillus Calmette-Guerin (BCG) is the most effective agent currently available to treat superficial bladder cancer. However, this form of therapy is not without potential serious or fatal complications. In addition to the potentially toxic systemic side effects attributed to hematogenous absorption of the bacillus, direct upper tract seeding may occur in patients with vesicoureteral reflux. We report on a patient treated with intravesical BCG for bladder cancer in whom unilateral necrotizing granulomatous pyelonephritis developed. Although severe, this complication is rare and we conclude that reflux is not a contraindication for intravesical BCG therapy.
- - - - - - - - - -
ranking = 1.25
keywords = bacillus
(Clic here for more details about this article)

3/14. Intravesical bacillus Calmette-Guerin for the treatment of superficial bladder cancer in renal transplant patients.

    BACKGROUND: Intravesical instillations with bacillus Calmette-Guerin (BCG) is considered the treatment of choice in the prophylaxis of high-grade superficial bladder carcinoma and in the treatment of carcinoma in situ (CIS) of the bladder. methods: There is no previous experience with BCG treatment in patients with renal transplantation. Theoretically, immunosuppression is a contraindication because of the risk of severe morbidity and sepsis. We present our experience with endovesical BCG in three renal transplant patients, under immunosuppressive treatment, with high-grade superficial bladder cancer and CIS. RESULTS: Two patients are free of disease at 17 and 60 months. One patient developed disease recurrence and underwent a radical cystectomy. There was neither change in renal function nor any clinical evidence of tuberculous infection. CONCLUSIONS: Intravesical BCG in superficial bladder cancer and/or CIS is a valid option, with no added morbidity to renal transplant patients.
- - - - - - - - - -
ranking = 1.25
keywords = bacillus
(Clic here for more details about this article)

4/14. Stromal invasion of the prostate following a complete response to bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the ureter and the bladder.

    bacillus Calmette-Guerin (BCG) instillation therapy is now a standard therapy for high-risk superficial bladder cancer patients. Although the complete response rate is approximately 70%, extra-vesical progression is sometimes observed. In particular, those patients who present a positive urinary cytology even after complete response from bladder lesion should be thoroughly examined. We present two cases of stromal invasion of the prostate after complete remission by BCG therapy of carcinoma in situ of the ureter and bladder found by transrectal prostate biopsy.
- - - - - - - - - -
ranking = 1
keywords = bacillus
(Clic here for more details about this article)

5/14. Vesicoureteral reflux after intravesical instillation of bacillus Calmette-Guerin against carcinoma in situ of the bladder.

    We report a case of vesicoureteral reflux (VUR) 3 years after intravesical instillation of bacillus Calmette-Guerin (BCG, tokyo 172 strain) against carcinoma in situ of the bladder. The present case suggests that a long-term careful follow-up is needed to detect not only tumor recurrences but also VUR as a late complication after intravesical BCG instillation.
- - - - - - - - - -
ranking = 1.25
keywords = bacillus
(Clic here for more details about this article)

6/14. The dangerous ureter.

    Seven patients with recurring transitional cell carcinoma of the urinary bladder were treated with repeated transurethral resections of these tumors and were given adjuvant intravesical chemotherapy or bacillus-Calmette Guerin (BCG) vaccine. Carcinoma either in the ureters or renal pelves subsequently developed in these patients. Unfortunately, 2 patients had inoperable tumors when the diagnosis was confirmed. When treating patients with recurring carcinoma of the urinary bladder, the possibility of upper urinary tract tumors developing must always be considered. Hence, the necessity of frequent urinary and ureteral cytology examinations proceeding to excretory urography, retrograde pyelograms, computerized tomography (CT) scans of the upper tracts, or ureteroscopy as may be necessary to locate small tumors or to diagnose carcinoma in situ.
- - - - - - - - - -
ranking = 0.25
keywords = bacillus
(Clic here for more details about this article)

7/14. Interstitial pneumonitis secondary to intravesical bacillus calmette-guerin for carcinoma in-situ of the bladder.

    We report an 81-year-old male who developed severe interstitial pneumonitis on maintenance intravesical bacillus Calmette-Guerin (BCG) for in-situ carcinoma of the bladder. The patient was treated with steroids and anti-tuberculin therapy with complete response. While there is no established standard of care for the treatment of interstitial pneumonitis, recent reports describe success with combination of corticosteroids and anti-tuberculin medications. We elected to follow this precedent and treated our patient with corticosteroids and antituberculin therapy with good outcome.
- - - - - - - - - -
ranking = 25.175845088097
keywords = calmette-guerin, bacillus
(Clic here for more details about this article)

8/14. Treatment of carcinoma in situ of the urethra with intraurethral instillations of bacillus Calmette-Guerin. Case report and review of literature.

    We present the case of a 60-year-old man with carcinoma in situ of the urethra after previous successful radiotherapy of an invasive bladder tumor. Intraurethral instillations with bacillus Calmette-Guerin were given. In spite of initial success, recurrences developed after two courses of 12 intraurethral instillations, and radical surgery was performed. The use of bacillus Calmette-Guerin is reviewed with regard to the locations of superficial transitional cell carcinoma outside the bladder cavity.
- - - - - - - - - -
ranking = 1.5
keywords = bacillus
(Clic here for more details about this article)

9/14. Complications after intravesical instillation of bacillus Calmette-Guerin: rhabdomyolysis and metastatic infection.

    Two cases of adverse reaction to bacillus Calmette-Guerin (BCG) bladder instillations are reported. In both cases transient fevers and systemic symptoms developed following the instillations. After an additional instillation 1 patient had high fevers, severe myalgias and profound weakness followed by rhabdomyolysis and anuric renal failure, which required 3 weeks of hemodialysis before recovery. Extensive evaluation revealed no cause other than the BCG instillations. In the other patient a firm subcutaneous nodule gradually developed on the chest wall, which contained nonviable acid fast bacilli.
- - - - - - - - - -
ranking = 1.25
keywords = bacillus
(Clic here for more details about this article)

10/14. BCG in management of transitional cell carcinoma invasive to prostate.

    Transitional cell carcinoma invading the prostate is a difficult problem to manage. Transurethral resection of the bladder neck followed by intravesical bacillus Calmette-Guerin (BCG) is one suggested option.
- - - - - - - - - -
ranking = 0.25
keywords = bacillus
(Clic here for more details about this article)
| Next ->


Leave a message about 'Carcinoma in Situ'


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.